ITCI · Intra-Cellular Therapies
Acquired Company
Johnson & Johnson acquired Intra-Cellular Therapies, Inc. on 4/2/2025 for $132.00 per share in cash, representing a total equity value of approximately $14.6 billion.
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
$131.87
Open
$131.87
Volume
N/A
Day Range
$131.87 - $131.87
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
2.48%
Institutional Own.
96.45%
Qtr Updated
Dec 31st 2024